NCT Number: NCT06056791
Phase: PHASE1|PHASE2
Trial Summary: This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The st – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Inmune Bio, Inc.
Acronym: CaRe
Study of INKmune in Patients With mCRPC (CaRe Prostate)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives